Calliditas Therapeutics AB (publ) (CALT)

Market Cap	562.48M
Revenue (ttm)	119.73M
Net Income (ttm)	-46.25M
Shares Out	28.12M
EPS (ttm)	-1.61
PE Ratio	n/a
Forward PE	18.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,521
Open	20.70
Previous Close	20.05
Day's Range	19.00 - 20.70
52-Week Range	15.25 - 29.30
Beta	1.40
Analysts	Strong Buy
Price Target	39.33 (+106.98%)
Earnings Date	May 14, 2024

About CALT

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2020
• Employees: 217
• Stock Exchange: NASDAQ
• Ticker Symbol: CALT

Financial Performance

In 2023, CALT's revenue was 1.21 billion, an increase of 50.32% compared to the previous year's 802.88 million. Losses were -466.19 million, 13.1% more than in 2022.

Financial numbers in SEK

Analyst Forecast

According to 3 analysts, the average rating for CALT stock is "Strong Buy." The 12-month stock price forecast is $39.33, which is an increase of 106.98% from the latest price.

Price Target

$39.33

(106.98% upside)

Analyst Consensus: Strong Buy